menu
    • menu
    [{"orgOrder":0,"company":"Teva Pharma (Thailand)","sponsor":"Lotus Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"THAILAND","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"Hypromellose","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Teva Pharma (Thailand)","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"Teva Pharma (Thailand) \/ Lotus Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Teva Pharma (Thailand) \/ Lotus Pharmaceuticals"}]

    Find Clinical Drug Pipeline Developments & Deals by Teva Pharma (Thailand)

    Menu

    Teva Pharma (Thailand)

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    Teva Pharma (Thailand)

    Thailand arrow
    ICHH-25
    Not Confirmed

    Teva Pharma (Thailand)

    Thailand arrow
    ICHH-25
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Hypromellose

    Therapeutic Area : Ophthalmology

    Study Phase : Approved

    Sponsor : Lotus Pharmaceuticals

    Deal Size : Undisclosed

    Deal Type : Acquisition

    DEALS_DEV arrow-down

    Taiwan's Lotus Pharma acquires Teva Pharma Thailand, expanding footprint in Southeast Asia

    Details : Lotus will gain access to Teva’s ophthalmic and respiratory portfolio, including NATEAR (hydroxypropyl methylcellulose) used as artificial tears to prevent conjunctival and corneal damage.

    Product Name : Natear

    Product Type : Small molecule

    Upfront Cash : Undisclosed

    June 06, 2024

    Lead Product(s) : Hypromellose

    Therapeutic Area : Ophthalmology

    Highest Development Status : Approved

    Sponsor : Lotus Pharmaceuticals

    Deal Size : Undisclosed

    Deal Type : Acquisition

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth